demonstrated that in TCGA datasets, the expression level of NALCN was significantly downregulated in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and colon adenocarcinoma (COAD), but upregulated in cholangiocarcinoma (CHOL), pheochromocytoma and paraganglioma (PCPG), stomach adenocarcinoma (STAD). This evidence concerns the gene NALCN and endocervical adenocarcinoma.